Adalimumab biosimilar (Hisun Pharma)

阿达木单抗生物类似药（海正药业）

Report date: 2022/03/10 16:44:29

Base Information

Drug NameAdalimumab biosimilar (Hisun Pharma)
Drug Alias NameRecombinant human anti-TNFα antibody (Hisun Pharma)重组抗TNFa全人单抗（海正药业）阿达木单抗生物仿制药（海正药业）Adalimumab (Hisun Pharma)adalimumab biosimilar +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/06
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHisun Biopharmaceutical Co Ltd
Inactive CompaniesZhejiang Hisun Pharmaceutical Co LtdHisun Pharmaceutical (Hangzhou) Co LtdInstitute Of Hygiene And Environmental Medicine Chinese Academy Of Military Medical Sciences
Active IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksWikipediaDrugBankKEGG